The US biopharma will discontinue development of the Exondys 51 (eteplirsen) follow up treatment to focus on other treatment ...

The two companies have formed Oblenio Bio to develop a tri-specific T-cell engager The U.S. company Aditum Bio and Chinese ...

The Simponi biosimilar, AVT05, has shown positive top-line results in patients with moderate to severe rheumatoid arthritis.

The Dutch biotech Synaffix and the Swiss company BigHat Biosciences announced yesterday that they have entered into a ...

New Darzelex SC quadruplet regimen approved by European Commission for newly diagnosed multiple myeloma patients.

The U.S. contract development and manufacturing organization (CDMO) Abzena announced yesterday that it has significantly ...

A new case study released by AllazoHealth reveals that a leading rare disease pharmaceutical company achieved a 10.4% ...

At CPHI Milan 2024, Abzena showcased its latest innovations in cell line development and ADC manufacturing, featuring the ...

UK-based private biotech company Ottimo Pharma has emerged from stealth mode after four years with the appointment of a ...

The acquisition of Aliada Therapeutics will grant AbbVie access to a neuroscience-focused technology platform and an ...

Anu Codaty, VP of global marketing and strategy at Aldevron, is blazing trails in biotech, inspired by a family legacy in ...